Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL66063 | 0.83 | CES1 (0.50) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL9317795 | 0.80 | CES1 (0.52) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL28779184 | 0.79 | CES1 (0.46) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL15265736 | 0.78 | CES1 (0.50) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL3113565 | 0.78 | CES1 (0.50) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL28268456 | 0.78 | CES1 (0.50) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL6299796 | 0.78 | CES1 (0.50) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL2424223 | 0.78 | CES1 (0.50) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL10823798 | 0.78 | CES1 (0.50) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL27293995 | 0.78 | CES1 (0.64) | CES1CES2AKR1B1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109776733-B | Polar diene polymer and preparation method thereof | 中国石油化工股份有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-107207421-B | Novel trifluoromethylpropionamide derivatives | 豪夫迈·罗氏有限公司 | 2021-04-20 | — | — | CN | claimed |
| US-10071984-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-09-11 | — | — | US | claimed |
| US-9980929-B2 | Trifluoromethylpropanamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-05-29 | — | — | US | claimed |
| EP-3262026-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2018-01-03 | — | — | EP | claimed |
| US-20170348257-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-12-07 | — | — | US | claimed |
| US-9676770-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-06-13 | — | — | US | claimed |
| WO-2016135070-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-01 | — | — | WO | claimed |
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | claimed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | claimed |
| US-20010011101-A1 | Alkylaminoalkyl-sulfonyl-terminated Beta-alanineamide amino-diol compounds for treatment of hypertension | HANSON GUNNAR J (US) | 2001-08-02 | — | — | US | claimed |
| US-5968984-A | Alkylaminoalkyl-sulfonyl-terminated β-alanineamide amino-diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1999-10-19 | — | — | US | claimed |
| US-5756549-A | RENIN INHIBITORS | G. D. SEARLE & CO. (US) | 1998-05-26 | — | — | US | claimed |
| US-5488066-A | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing cycloalkyl-alanine amino-diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1996-01-30 | — | — | US | claimed |
| US-5488067-A | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1996-01-30 | — | — | US | claimed |
| US-5432201-A | Alkylaminoalkyl-sulfonyl-terminated β-alanineamide amino-diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1995-07-11 | — | — | US | claimed |
| US-5416119-A | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing cycloalkyl-alanine amino-diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1995-05-16 | — | — | US | claimed |
| US-5414018-A | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1995-05-09 | — | — | US | claimed |
| WO-1995008531-A1 | ALKYLAMINOALKYL-TERMINATED SULFIDE/SULFONYL-CONTAINING PROPARGYL AMINO-DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1995-03-30 | — | — | WO | claimed |
| US-RE29577-E | Anthraquinone dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1978-03-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348257-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | PRMT7, GFRA3, PRMT5 | CES1 348/4885CES2 44/4885AKR1B1 628/4885 |
| US-20010011101-A1 | Alkylaminoalkyl-sulfonyl-terminated Beta-alanineamide amino-diol compounds for treatment of hypertension | REN, AGTR1, AGT | CES1 140/4885CES2 266/4885AKR1B1 231/4885 |
| US-10071984-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM3B | CES1 564/4885CES2 1984/4885AKR1B1 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.